ライフサイエンスコーパス: QALY

1 QALYs were higher in the psychosocial intervention group

2 $100,00/QALY was considered the US cost-effectiveness upper limi

3 s ratios (ICERs) were compared to a $100 000/QALY gained willingness-to-pay threshold.

4 and costly than GT, with an ICER > $100 000/QALY, compared to GT.

5 the willingness-to-pay threshold of $100 000/QALY.

6 % of simulations at a threshold of <$100 000/QALY; conclusions were similar from the societal perspec

7 ansmissions, screening Yearly was <=$100,000/QALY (ICER: $70,900/QALY).

8 d to below the typical threshold of $100,000/QALY gained.

9 reach the typical benchmark of ${\$}$100,000/QALY gained.

10 colectomy becomes cost-effective at $100,000/QALY if robotic disposable instrument costs decrease bel

11 c+asymptomatic-monthly had an ICER <$100,000/QALY only when Re >=1.6; when test cost was <=$3, every

12 tide in 68% of iterations at a ${\$}$100,000/QALY threshold.

13 utide use in 80% of iterations at a $100,000/QALY threshold.

14 life-year saved [QALY]; threshold <=$100,000/QALY).

15 sed life expectancy by 8.2 years at $129,000/QALY gained (95% uncertainty interval, $90,000 to $219,0

16 fectiveness ratio <$50 000/QALY or <$150 000/QALY was 1% and 25%, respectively.

17 th CAR-T therapies meet a less than $150,000/QALY threshold.

18 tisagenlecleucel to cost less than $150,000/QALY, even at 25% PFS.

19 e modest (6.4 years) and expensive ($159,000/QALY gained [95% uncertainty interval, $105,000 to $284,

20 sed life expectancy by 4.6 years at $168,000/QALY gained (95% uncertainty interval, $105,000 to $414,

21 uncertainty interval, $123,000 to $1,170,000/QALY]).

22 cremental cost-effectiveness ratio >$200 000/QALY gained, PCDT is not an economically attractive trea

23 ler (3.4 years) and more expensive ($223,000/QALY gained [95% uncertainty interval, $123,000 to $1,17

24 % uncertainty interval, $105,000 to $414,000/QALY).

25 er a willingness-to-pay threshold of $50 000/QALY gained.

26 etal willingness-to-pay threshold of $50 000/QALY in approximately 64.4% of the clinical scenarios.

27 ncremental cost-effectiveness ratio <$50 000/QALY or <$150 000/QALY was 1% and 25%, respectively.

28 a conservative willingness to pay of $50 000/QALY, there is room to expand services to improve patien

29 illingness-to-pay (WTP) threshold of $50,000/QALY were considered cost effective.

30 ng a willingness-to-pay threshold of $50,000/QALY.

31 9% of the time at a WTP threshold of $50,000/QALY.

32 ngness-to-pay threshold for Korea of $56,000/QALY gained.

33 egnant women was cost-effective (ICER $6,000/QALY) and should be recommended nationally.

34 of $40,371/QALY, $335,726/QALY, and $168,006/QALY, respectively.

35 rategy 44) cost an additional $478 for 0.009 QALYs gained per CDI patient, resulting in an ICER of $3

36 ears, median difference using warfarin 0.010 QALYs [95% CI, 0.009-0.013], median difference using api

37 probability of being more effective (+0.023 QALYs; 95% confidence interval [CI], 0.004 to 0.044) and

38 013], median difference using apixaban 0.025 QALYs [95% CI, 0.024-0.026]).

39 perspective CUR for bevacizumab was $11,033/QALY, $79,600/QALY for ranibizumab, and $44,801/QALY for

40 patient), with ICERs between $490 and $1,037/QALY.

41 illion, while the 2006 NKAS generated 44 040 QALYs and cost pound 625 million.

42 ost-effectiveness ratio for PCDT of $222 041/QALY gained.

43 ve among people with diabetes (from $223,041/QALY gained in California to $817,753 /QALY in New York)

44 QALY maximization approach generated 48 045 QALYs and cost pound 681 million, while the 2006 NKAS ge

45 78 823, an incremental effectiveness of 0.05 QALYs, and an ICER of $9 810 360 per QALY when compared

46 ntions with ICER values ranging from $94 069/QALY in Los Angeles to $146 256/QALY in Miami.

47 t ($346 500) and lower health benefits (9.09 QALYs).

48 clinically relevant lifetime benefit as 0.10 QALYs.

49 ng any heart gained 0.14 life-years and 0.11 QALYs, while increasing costs by $9418/patient.

50 , 40 to 170 QALYs) lost due to death, and 15 QALYs (UI, 6 to 32 QALYs) lost due to illness; this impl

51 (1.34 QALYs with intraoperative MRI vs 1.16 QALYs without) at an incremental cost of $13 447 ($176 4

52 flibercept conferred 0.141, 0.141, and 0.164 QALY gains, respectively, with corresponding average CUR

53 UI, 3 to 11 deaths), 81 QALYs (UI, 40 to 170 QALYs) lost due to death, and 15 QALYs (UI, 6 to 32 QALY

54 e MRI yielded an incremental benefit of 0.18 QALYs (1.34 QALYs with intraoperative MRI vs 1.16 QALYs

55 s and beyond, with lifetime ICERs of $18,184/QALY (F&V incentive) and $13,194/QALY (healthy food ince

56 f $165 985/QALY, $325 860/QALY, and $399 189/QALY, respectively.

57 f $165,985/QALY, $325,860/QALY, and $399,189/QALY, respectively.

58 n South Africa, PGT gained 15 life-years (19 QALYs) and cost $33 182 per 1000 patients, a value of $1

59 of $18,184/QALY (F&V incentive) and $13,194/QALY (healthy food incentive).

60 tal perspective) improved the ICER to $6,200/QALY gained (95% CI, cost-saving $24,300).

61 a sustained viral response (SVR), with 7.21 QALYs and a $245 500 lifetime cost, compared to 22% achi

62 zil, PGT gained 19 discounted life-years (23 QALYs) and cost $11 064 per 1000 patients, a value of $4

63 In India, PGT gained 20 life-years (24 QALYs) and cost $13 195 per 1000 patients, a value of $5

64 averting 78.0% HIV infections and add 29,242 QALYs at a cost of $51,597 per QALY gained, which is wit

65 DAA at 20% coverage had an ICER of $27,251/QALY.

66 from $94 069/QALY in Los Angeles to $146 256/QALY in Miami.

67 b was associated with an improvement of 0.26 QALYs and 0.40 life-years compared with using ibrutinib

68 that is superior to cataract surgery ($2,262/QALY), amblyopia therapy ($2,710/QALY), and retinal deta

69 rom $2,828/QALY gained in Florida to $11,265/QALY gained in New York) and least cost-effective among

70 llion in direct costs and a gain of 4,049.28 QALYs over 20 years.

71 th sequencing leading to an additional 14.28 QALYs gained.

72 2.64 QALYs) and 2.68 (95% CrI, 2.11 to 3.28 QALYs) in the interval CRS plus HIPEC group.

73 The ICER amounted to euro 28,299/QALY.

74 dditional costs of pound 39 316, with a 0.30 QALY gain compared with methotrexate alone, resulting in

75 ime cost per person, with an ICER of $34 300/QALY, compared to no intervention.

76 ALY), and retinal detachment repair ($45,304/QALY).

77 A 12-month biopsy cost $13 318/QALY for the base-case cohort.

78 lost due to death, and 15 QALYs (UI, 6 to 32 QALYs) lost due to illness; this implies a cost-effectiv

79 ranibizumab each conferred an 11-year, 1.339 QALY gain versus observation.

80 Nonadherent patients had a mean loss of 0.34 QALYs, resulting in a cost-effectiveness ratio of $29 60

81 d an incremental benefit of 0.18 QALYs (1.34 QALYs with intraoperative MRI vs 1.16 QALYs without) at

82 lysis, a clinical effectiveness gain of 1.35 QALY justified an increased incremental cost of $2140.

83 ation, adding teduglutide cost ${\$}$124,353/QALY gained.

84 fective with 12-month biopsy costing $46 370/QALY.

85 , with corresponding average CURs of $40,371/QALY, $335,726/QALY, and $168,006/QALY, respectively.

86 V infections and facilitate a gain of 37,372 QALYs at a cost of $274,822 per QALY gained over 20 year

87 Aflibercept conferred a 1.380 QALY gain.

88 and immediate thrombectomy strategy was 0.39 QALY, which corresponds to 142 days in perfect health pe

89 ars), compared with 5.30 (95% CI, 5.20-5.39) QALYs and $63 040 (95% CI, $37 624-$102 260) for medical

90 EK instead of a DSAEK generated an extra 0.4 QALYs over a 15-year period.

91 ost-effectiveness ratio [ICER] $5,387-$8,430/QALY), depending on whether diagnostic testing had lasti

92 events by 8% (7-9; 49 events), and raise 44 QALYs (40-49) for the study population.

93 ffective compared to bevacizumab ($1,151,451/QALY incremental CUR).

94 st, compared to 22% achieving SVR, with 5.49 QALYs and a $161 300 lifetime cost, with no intervention

95 espective ICERs were $14,576/QALY and $9,497/QALY.

96 lthcare costs only, the program cost $25,500/QALY gained (95% CI $12,600-$48,600).

97 g 3-monthly was cost-effective (ICER: $4,500/QALY) compared to SQ and reduced primary transmissions t

98 emental cost-effectiveness ratio of $137 526/QALY; for femoral-popliteal DVT, standard therapy was an

99 It is also highly cost-effective ($1,574/QALY), with an average cost-utility ratio vs. no therapy

100 y ratio in 2018 U.S. real dollars was $1,574/QALY.

101 productivity, respective ICERs were $14,576/QALY and $9,497/QALY.

102 UR for bevacizumab was $11,033/QALY, $79,600/QALY for ranibizumab, and $44,801/QALY for aflibercept.

103 ental cost-effectiveness ratio of euro 9,600/QALY.

104 g any heart was cost effective (ICER $85 602/QALY gained).

105 f IVA compared with that of IVB was $153 633/QALY from the third-party facility setting and $152 992/

106 al CRS group was 2.12 (95% CrI, 1.66 to 2.64 QALYs) and 2.68 (95% CrI, 2.11 to 3.28 QALYs) in the int

107 incremental cost-effectiveness ratio $27,700/QALY).

108 r men with negative imaging results ($22,706/QALY gained relative to mpMRI alone); this strategy redu

109 Multifocal IOLs were associated with a 0.71 QALY increase at an increased cost of $3,415 compared wi

110 ery ($2,262/QALY), amblyopia therapy ($2,710/QALY), and retinal detachment repair ($45,304/QALY).

111 aroscopy, resulting in an ICER of $2,322,715/QALY because of minimal differences in QOL.

112 nding average CURs of $40,371/QALY, $335,726/QALY, and $168,006/QALY, respectively.

113 ategy (cost = $24 572, effectiveness = 13.73 QALYs), showing the lowest cost and highest effectivenes

114 more cost-effective with an ICUR of $1587.73/QALY.

115 al cost-effectiveness ratio of pound 110 741/QALY compared with the QALY maximization approach.

116 3,041/QALY gained in California to $817,753 /QALY in New York).

117 age 45 years instead of 50 years cost $7700/QALY gained.

118 Y, $79,600/QALY for ranibizumab, and $44,801/QALY for aflibercept.

119 monofocal IOLs, leading to an ICER of $4,805/QALY from the societal and health care sector perspectiv

120 d, causing 5 deaths (UI, 3 to 11 deaths), 81 QALYs (UI, 40 to 170 QALYs) lost due to death, and 15 QA

121 e among persons living with HIV (from $2,828/QALY gained in Florida to $11,265/QALY gained in New Yor

122 more cost-effective with an ICUR of $699.84/QALY.

123 339 more per case with an ICER of $4,174,849/QALY.

124 overage had ICERs of $165 985/QALY, $325 860/QALY, and $399 189/QALY, respectively.

125 overage had ICERs of $165,985/QALY, $325,860/QALY, and $399,189/QALY, respectively.

126 hybrid (18)F-choline PET/mpMRI cost $46,867/QALY gained relative to mpMRI alone.

127 ty-adjusted life-years (QALYs), cost $33,900/QALY gained, and required 758 additional colonoscopies.

128 ng Yearly was <=$100,000/QALY (ICER: $70,900/QALY).

129 the base scenario, teduglutide cost $949,910/QALY gained.

130 value compared to MAT+ at 80% alone ($23 932/QALY).

131 le value compared to MAT+ 80% alone ($23,932/QALY).

132 lysis, a clinical effectiveness gain of 2.98 QALY justified a higher incremental cost of $2085.00.

133 40%, and 80% coverage had ICERs of $165 985/QALY, $325 860/QALY, and $399 189/QALY, respectively.

134 40%, and 80% coverage had ICERs of $165,985/QALY, $325,860/QALY, and $399,189/QALY, respectively.

135 he third-party facility setting and $152 992/QALY from the societal perspective.

136 tional Kidney Allocation Scheme (NKAS) and a QALY maximization approach designed to maximize health g

137 Compared with the 2006 NKAS, a QALY maximization approach makes more efficient use of d

138 cient than SIT, resulting in 0.33 additional QALYs and a $14 100 lower lifetime cost per person, with

139 oduced estimates of total lifetime costs and QALYs for each allocation scheme.

140 e coverage, number of additional deaths, and QALYs lost from increased mortality and morbidity, all p

141 oductivity loss) costs (in 2018 dollars) and QALYs lost because of uncontrolled asthma from 2019 to 2

142 reducing teduglutide cost decreased the cost/QALY gained to below the typical threshold of $100,000/Q

143 d 6-7 CRC deaths and gained 27-28 discounted QALYs while saving $163,700-$445,800.

144 For iliofemoral DVT, QALY gains with PCDT were greater, yielding an increment

145 The strategy resulted in fewer QALYs due to more false negatives but an ICER of $3,012,

146 is not cost-effective in the short term for QALYs due to a ceiling effect in quality of life.

147 Aflibercept conferred greater QALY gain for less cost than ranibizumab but was not cos

148 In model projections, CBT produced higher QALYs (3 days more at 1 year and 20 days more at 5 years

149 Compared with standard care, NHVs increased QALYs (2.49 vs. 2.25) and costs ($81 327 vs. $76 705), r

150 pixaban did not decrease below 0.10 lifetime QALYs until after age 92.

151 with warfarin decreased below 0.10 lifetime QALYs while NCB associated with apixaban did not decreas

152 The estimated lifetime QALYs gained were 5.9 and 5.4 in the PR and PPV groups,

153 isks of recurrent stroke, dementia and lower QALYs after lobar ICH highlight the need for more effect

154 dard biopsy was more expensive and had lower QALYs than performing no biopsy.

155 There was no significant difference in mean QALY between groups at 6 months (0.3 vs 0.3; difference,

156 The mean QALY in the interval CRS group was 2.12 (95% CrI, 1.66 t

157 poor metabolizers (43 individuals) with mean QALYs of 4.18 (95%CI: 3.16-5.55) versus 3.02 (95%CI: 1.9

158 t 1.93 million CVD events, gain 4.64 million QALYs, and save $39.7 billion in formal healthcare costs

159 ALYs, AIMS resulted in higher costs but more QALYs compared to TAU, which resulted in an ICER of euro

160 k of a value set allowing the calculation of QALY is an important limitation when establishing the va

161 In terms of QALYs, AIMS resulted in higher costs but more QALYs comp

162 tiveness (in quality-adjusted life years, or QALYs) of treatment compared with no teduglutide use, wi

163 y threshold of $100,000, $50,000, and $0 per QALY if it results in a decrease in risk of transplant f

164 cost-effectiveness threshold of $104 000 per QALY (UI, $51 000 to $209 000 per QALY) in 2019 U.S. dol

165 iveness ratios remained below US$100,000 per QALY across a wide variety of sensitivity analyses.

166 lity that the threshold exceeds $150 000 per QALY and about 48% probability that it lies below $100 0

167 ERs above the range $100 000 to $150 000 per QALY are unlikely to be cost-effective in the United Sta

168 ZVL yielded an ICER of less than $60 000 per QALY for persons aged 60 years or older.

169 In contrast, ICERs were > $175,000 per QALY gained for all strategies for low-risk survivors, r

170 t long-term with MSD VCV at pound 20,000 per QALY gained threshold.

171 Strategies with ICERs < $100,000 per QALY gained were considered cost-effective.

172 willingness-to-pay threshold of $100 000 per QALY gained, atrial fibrillation ablation was found to b

173 -year (QALY) in all markets and $200 000 per QALY in the USA.

174 willingness-to-pay threshold of $100 000 per QALY showed buprenorphine-naloxone to be preferable to e

175 04 000 per QALY (UI, $51 000 to $209 000 per QALY) in 2019 U.S. dollars.

176 eration TKI (willingness to pay $200 000 per QALY, 66% of patients achieving sustained deep molecular

177 esholds of pound 20 000 and pound 30 000 per QALY, respectively.

178 year and a willingness to pay of $50 000 per QALY, the annual price of second-generation TKIs should

179 cietal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per yea

180 probability that it lies below $100 000 per QALY.

181 willingness-to-pay threshold of $150 000 per QALY.

182 s or older, ICERs were less than $60 000 per QALY.

183 pay threshold of pound 20,000 to 30,000 per QALY.

184 inty interval [UI], $51 000 to $215 000) per QALY.

185 cost $308 000 (UI, $197 000 to $678 000) per QALY.

186 ost-effectiveness ratio of pound 129 025 per QALY gained.

187 700), resulting in an ICER of $2 350 041 per QALY.

188 RV; and from pound 9,220 to pound 27,101 per QALY gained with MMRV-MMRV (payer perspective).

189 ito season was cost-effective at $81 123 per QALY (95% CI, -$49 138 to $978 242 per QALY).

190 182 per 1000 patients, a value of $1780 per QALY gained.

191 l cost-effectiveness ratio was US$92,200 per QALY (base case).

192 st $170 per infection prevented ($49 200 per QALY) compared with masks alone.

193 3 per QALY (95% CI, -$49 138 to $978 242 per QALY).

194 which resulted in an ICER of euro 27759 per QALY gained.

195 of 0.05 QALYs, and an ICER of $9 810 360 per QALY when compared with second-line use.

196 0 (US$26,000) and pound 30,000 ($39,386) per QALY, respectively.

197 tal cost-effectiveness ratio was $74 403 per QALY gained.

198 tlanta, Baltimore, and Miami, to $95 416 per QALY in Seattle.

199 s-to-pay ratio of pound 20,000 ($28,433) per QALY.

200 ntal cost-effectiveness ratio of $76 442 per QALY.

201 mental cost-effectiveness ratio of $4684 per QALY gained.

202 1 064 per 1000 patients, a value of $476 per QALY gained.

203 ent was $38 496 (95% CI, $5583-$117 510) per QALY gained.

204 3 195 per 1000 patients, a value of $546 per QALY gained.

205 76 705), resulting in an ICER of $19 570 per QALY gained.

206 nd add 29,242 QALYs at a cost of $51,597 per QALY gained, which is within the willingness-to-pay thre

207 in a cost-effectiveness ratio of $29 600 per QALY gained.

208 ental cost-effectiveness ratio of $4,684 per QALY gained.

209 ncremental cost-utility ratio of $51,694 per QALY gained.

210 averaging $49 200, $68 600, and $96 700 per QALY, respectively.

211 patient, resulting in an ICER of $31 751 per QALY, below the willingness-to-pay threshold of $100 000

212 fectiveness was estimated at pound 1,760 per QALY, with the probability of the intervention being cos

213 The cost was US$41,800 per QALY in patients with baseline LDL-C >=100 mg/dl, wherea

214 in of 37,372 QALYs at a cost of $274,822 per QALY gained over 20 years relative to the status quo.

215 QALY (CI, $125 million to $2.90 billion per QALY) compared with no screening in the 50 states.

216 The cost per QALY for facility and nonfacility settings was $751 and

217 ented to between $2010 and $17 210 (cost per QALY gained, $811 400 to $2 804 600).

218 er cost or worse outcomes at higher cost per QALY gained.

219 IV infections, but at an increasing cost per QALY gained.

220 TBS plus cataract surgery showed a cost per QALY of C$62 366 or less.

221 in those with LDL-C <100 mg/dl the cost per QALY was US$299,400.

222 rcept maintains acceptable lifetime cost per QALY while having a favorable cost utility compared with

223 erspective, the estimated lifetime costs per QALY in the facility and nonfacility settings were $39 3

224 erspective, the estimated lifetime costs per QALY in the facility setting were $52 754 for IVB, $128

225 f pound 20,000 ($28,433 in U.S. dollars) per QALY, 77.2% of the cost-effectiveness model iterations f

226 ost $997 000 (UI, $254 000 to dominated) per QALY.

227 -effectiveness ratio of $100 000 or less per QALY at 1 year; CBT had a 73% to 77% likelihood at 5 yea

228 Universal ID-NAT cost $341 million per QALY (CI, $125 million to $2.90 billion per QALY) compar

229 for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF wa

230 EP, with an ICER of more than $7 million per QALY.

231 ess-to-pay thresholds of $50 000 or more per QALY gained.

232 (ICERs, $/quality-adjusted life-year saved [QALY]; threshold <=$100,000/QALY).

233 mong patients who received a transplant, the QALY maximization approach generated 48 045 QALYs and co

234 atio of pound 110 741/QALY compared with the QALY maximization approach.

235 tion of macular pathologies and improved the QALYs over time.

236 nsplant, the 2006 NKAS produced higher total QALYs and costs and an incremental cost-effectiveness ra

237 ifetime cost per quality-adjusted life year (QALY) for the treatment of RRD with PR or PPV.

238 as USD 9,080 per quality-adjusted life year (QALY) gained in 60-year-old patients.

239 of $100 000 per quality-adjusted life year (QALY) gained was used to determine cost efficacy.

240 3 (20 years) per quality-adjusted life year (QALY) gained with V-MMRV; and from pound 9,220 to pound

241 mental costs per quality-adjusted life year (QALY) gained.

242 t in dollars per quality-adjusted life year (QALY) gained.

243 costs and higher Quality-Adjusted Life Year (QALY) gains.

244 pound 1,359 per quality-adjusted life year (QALY), but there was insufficient evidence of effect on

245 than $30 000 per quality-adjusted life-year (QALY) gained compared with low-intensity surveillance.

246 ) in dollars per quality-adjusted life-year (QALY) gained indicates whether treatments are likely to

247 t of $57,180 per quality-adjusted life-year (QALY) gained.

248 lds: $50 000 per quality-adjusted life-year (QALY) in all markets and $200 000 per QALY in the USA.

249 emental cost per quality-adjusted life-year (QALY) was determined with the addition of alirocumab ver

250 $50,000 USD per quality-adjusted life-year (QALY), the report concludes that the limit of cost-effec

251 0 to $47 000 per quality-adjusted life-year (QALY), using a societal perspective and assuming 100% co

252 sed as euros per quality-adjusted life-year (QALY), was calculated from a Dutch societal perspective,

253 ICER) of $27 251/quality-adjusted life-year (QALY).

254 pound 30,000 per quality-adjusted life-year (QALY).

255 rategy increased quality-adjusted life year (QALYs) by 69,700 and costs by euro 670 million, yielding

256 veness (cost per quality-adjusted life year [QALY] gained) for TTT in each modeled population.

257 ratios (ICER, $/quality-adjusted life-year [QALY]).

258 ted in 2016 US$/quality-adjusted life years (QALY), discounted 3% annually, from the healthcare secto

259 tcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis c

260 l health]); and quality-adjusted life-years (QALY; range: 0 [dead] to 0.5 [full health at 6 months]).

261 CI, 5.89-6.93) quality-adjusted life years (QALYs) and a total cost of $105 657 (95% CI, $55 311-$19

262 sy yielded more quality-adjusted life years (QALYs) at lower cost.

263 it expressed as quality adjusted life years (QALYs) in a large group of 571 individuals of Italian or

264 of $16 740 and quality-adjusted life years (QALYs) of 0.08, yield an incremental cost-effectiveness

265 etime costs and quality-adjusted life years (QALYs) over a 10-year time horizon with and without a ja

266 0.37 additional quality-adjusted life years (QALYs) per patient.

267 impact in total quality-adjusted life years (QALYs) was relatively modest, with sequencing leading to

268 The 10-year quality-adjusted life years (QALYs) were also lower after lobar versus non-lobar ICH

269 al costs, total quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER)

270 lth care costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs

271 e resource use, quality-adjusted life years (QALYs), and productivity loss across control levels.

272 Deaths averted, quality-adjusted life years (QALYs), cost, and incremental cost-effectiveness ratios

273 ion in terms of quality-adjusted life years (QALYs), costs, and access to transplantation.

274 18 dollars) and quality-adjusted life years (QALYs), discounted at 3% annually.

275 ases prevented, quality-adjusted life years (QALYs), health-related costs (formal healthcare, informa

276 veness based on quality-adjusted life years (QALYs), taking a public sector perspective.

277 en converted to quality-adjusted life years (QALYs).

278 ere measured in quality-adjusted life years (QALYs).

279 no treatment in quality-adjusted life years (QALYs).

280 lifetime costs; quality-adjusted life years (QALYs); and incremental cost-effectiveness ratios.

281 fectiveness [in quality-adjusted life years (QALYs)] of using teduglutide compared with offering inte

282 ected costs and quality-adjusted life-years (QALYs) gained that used data on participants' treatment

283 s prevented and quality-adjusted life-years (QALYs) gained, and screening costs.

284 Rs), costs, and quality-adjusted life-years (QALYs) gained.

285 atest number of quality-adjusted life-years (QALYs) was generated by risk-based screening at a 10-yea

286 scounted costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs

287 nce among PWID, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs

288 18 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

289 ectomy was 2.38 quality-adjusted life-years (QALYs), and the average cost-utility ratio in 2018 U.S.

290 aths, gained 14 quality-adjusted life-years (QALYs), cost $33,900/QALY gained, and required 758 addit

291 were discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios

292 fetime HF risk, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectivene

293 HIV infections, quality-adjusted life-years (QALYs), total cost (in 2018 US$), and incremental cost-e

294 ere measured in quality-adjusted life-years (QALYs).

295 also calculated quality-adjusted life-years (QALYs).

296 sed in terms of quality-adjusted life-years (QALYs).

297 th outcomes (in quality-adjusted life-years [QALYs]) over a lifetime horizon, using new HCV drug cost

298 benefits (9.26 quality-adjusted life-years [QALYs]).

299 and long term (quality-adjusted life-years [QALYs]).

300 ealth outcomes (quality-adjusted life-years, QALYs) between cohorts willing to accept any heart and t